To determine the role of PAK1 in the effect of the ATRA and Sorafenib combination, we selected two human HCC tissues with remarkably differential PAK1 expression and established PDX models that were treated with ATRA and Sorafenib either alone or in combination (Figs. S2 and S3). The gene discussed is PAK1; the disease is hepatocellular carcinoma.